Drugmakers Eli Lilly and Amylin Pharmaceuticals are ending their development agreement for diabetes drugs and are resolving litigation between the companies.
Topstories, Indianapolis Star
Tue, 11/08/2011 - 7:31am
Drugmakers Eli Lilly and Amylin Pharmaceuticals are ending their development agreement for diabetes drugs and are resolving litigation between the companies.